Vitamin K (PIVKA-II): Drugs That Distort This Test

What PIVKA-II Actually Measures

PIVKA-II stands for Protein Induced by Vitamin K Absence or Antagonism-II. It is an abnormal form of prothrombin (clotting factor II) that the liver produces when vitamin K is not available to complete the gamma-carboxylation step. Clinicians order it for two distinct reasons: to assess vitamin K status and to screen for hepatocellular carcinoma.

The Gamma-Carboxylation Step

Vitamin K acts as a cofactor for the enzyme gamma-glutamyl carboxylase. This enzyme adds a carboxyl group to specific glutamic acid residues on prothrombin, allowing the protein to bind calcium and participate in the coagulation cascade. When the vitamin K supply is blocked, whether by diet, malabsorption, or drug interference, the liver still produces prothrombin but in a non-functional, under-carboxylated form. That molecule is PIVKA-II 1.

PIVKA-II as a Tumor Marker

Hepatocellular carcinoma cells produce PIVKA-II through a mechanism that appears independent of systemic vitamin K levels. A 2014 meta-analysis covering 3,659 HCC patients found that PIVKA-II at a cutoff of 40 mAU/mL had a pooled sensitivity of 71% and specificity of 84% for HCC detection 2. The American Association for the Study of Liver Diseases (AASLD) notes PIVKA-II as a complementary marker alongside alpha-fetoprotein (AFP), and combining both markers raises sensitivity to approximately 80% 3.

A falsely elevated PIVKA-II from a drug effect can trigger unnecessary imaging, biopsy, or patient anxiety. A falsely normalized PIVKA-II from vitamin K supplementation can mask early-stage HCC. Both scenarios carry real clinical consequences.

Warfarin and Vitamin K Antagonists: The Largest Confounder

Warfarin directly inhibits vitamin K epoxide reductase (VKORC1), the enzyme that recycles vitamin K back to its active form. This is the same pathway that gamma-glutamyl carboxylase depends on. Every patient on warfarin will have elevated PIVKA-II. The elevation is not subtle.

How High Does Warfarin Push PIVKA-II?

A study by Liebman et al. Found that patients on stable warfarin therapy had PIVKA-II levels ranging from 800 to over 10,000 mAU/mL, compared with the normal reference of <40 mAU/mL 4. At these concentrations, PIVKA-II loses all diagnostic value for HCC screening.

Other Vitamin K Antagonists

Acenocoumarol and phenprocoumon, used widely in Europe, produce the same effect. Any agent that targets the vitamin K cycle will raise PIVKA-II. The Japan Society of Hepatology guidelines explicitly state: "PIVKA-II should not be used for HCC surveillance in patients receiving warfarin or other vitamin K antagonists" 5.

Clinical Guidance

If PIVKA-II testing is necessary for HCC screening in a patient on warfarin, the standard recommendation is to discontinue warfarin for at least 48 to 72 hours (under physician supervision and with bridging anticoagulation if indicated), then re-draw the specimen. The AASLD 2018 practice guidance advises interpreting PIVKA-II "with caution in patients on vitamin K antagonists" 3.

Broad-Spectrum Antibiotics

The human gut microbiome produces menaquinones (vitamin K2 subtypes MK-7 through MK-13), which contribute to systemic vitamin K pools. Broad-spectrum antibiotics that suppress anaerobic gut bacteria can reduce menaquinone synthesis enough to shift PIVKA-II upward.

High-Risk Antibiotic Classes

Fluoroquinolones, carbapenems, and extended-spectrum penicillins have all been associated with subclinical vitamin K depletion. A 1988 prospective study of 40 ICU patients on broad-spectrum antibiotics found detectable PIVKA-II in 31% of patients who had normal levels at admission, with the median time to elevation being 7 to 10 days of antibiotic therapy 6.

NMTT-Containing Cephalosporins

Cephalosporins with the N-methylthiotetrazole (NMTT) side chain deserve separate discussion. Cefotetan, cefoperazone, and cefamandole directly inhibit the vitamin K epoxide reductase enzyme, producing a warfarin-like effect. This is a pharmacologic blockade, not merely a gut-flora disruption. Case series from the 1980s documented clinical bleeding in patients on cefoperazone, with PIVKA-II levels exceeding 200 mAU/mL 7.

Practical Framework for Antibiotic Interference

| Risk Tier | Agents | Mechanism | Expected PIVKA-II Shift | |---|---|---|---| | High | Cefotetan, cefoperazone | Direct VKORC1 inhibition (NMTT side chain) | 5x to 50x above reference | | Moderate | Meropenem, piperacillin-tazobactam, moxifloxacin | Gut flora suppression reducing menaquinone synthesis | 1.5x to 5x above reference | | Low | Narrow-spectrum agents (amoxicillin, azithromycin) | Minimal flora disruption | Typically no clinically significant change |

If a patient on prolonged broad-spectrum antibiotics needs PIVKA-II testing, consider waiting 2 weeks after antibiotic completion, or supplement with phytonadione (vitamin K1) 10 mg orally for 3 days before the draw to re-saturate stores.

Fat Malabsorption Agents

Vitamin K is fat-soluble. Any drug that reduces dietary fat absorption will reduce vitamin K absorption along with it.

Orlistat

Orlistat inhibits pancreatic lipase, blocking approximately 30% of dietary triglyceride absorption. A randomized trial of 17 healthy subjects on orlistat 120 mg three times daily for 4 weeks showed a 42% reduction in serum phylloquinone (vitamin K1) and a statistically significant rise in under-carboxylated osteocalcin, another vitamin K-dependent protein 8. PIVKA-II was not measured in that trial, but the biochemical principle is identical: reduced vitamin K substrate leads to increased under-carboxylated clotting factors.

Bile Acid Sequestrants

Cholestyramine, colesevelam, and colestipol bind bile acids in the intestinal lumen. Bile acids are required for fat-soluble vitamin absorption. Long-term cholestyramine use has been associated with vitamin K depletion severe enough to prolong prothrombin time (PT), and by extension, to raise PIVKA-II 9. The Endocrine Society recommends monitoring fat-soluble vitamin levels in patients on prolonged bile acid sequestrant therapy.

Patients on either orlistat or bile acid sequestrants who need PIVKA-II testing for HCC surveillance should receive vitamin K1 supplementation (1 to 10 mg daily) for at least 1 week before the blood draw to normalize the substrate pool.

Anticonvulsants and Hepatic Enzyme Inducers

Phenytoin, phenobarbital, and carbamazepine induce hepatic cytochrome P450 enzymes that accelerate catabolism of vitamin K. Neonates born to mothers on anticonvulsants have well-documented vitamin K deficiency bleeding (previously called hemorrhagic disease of the newborn), and PIVKA-II is often the earliest detectable marker in this population 10.

Adult Impact

In adults, the effect is more subtle. A cross-sectional study of 89 epilepsy patients on long-term phenytoin found that 18% had detectable PIVKA-II (defined as above 2 ng/mL by ELISA), compared with 3% of age-matched controls 11. The elevation was modest, typically in the 2 to 8 ng/mL range, but enough to push values above the diagnostic threshold for some assays.

Rifampin

The potent CYP inducer rifampin also accelerates vitamin K turnover. Patients on tuberculosis treatment regimens that include rifampin should have PIVKA-II results interpreted with this in mind, particularly if they are also being monitored for hepatotoxicity from isoniazid.

Vitamin E at Supraphysiologic Doses

Alpha-tocopherol (vitamin E) antagonizes vitamin K at the gamma-carboxylase step when taken at doses above 800 IU/day. A controlled feeding study in 12 adults given 1,000 IU/day of alpha-tocopherol for 12 weeks found significant increases in PIVKA-II compared with placebo (P = 0.004) 12. The mechanism involves competitive inhibition: vitamin E structurally resembles vitamin K and occupies the binding site on gamma-glutamyl carboxylase.

Standard multivitamin doses of vitamin E (15 to 30 IU) do not produce this interference. The clinical threshold appears to be around 400 IU/day or higher, with consistent elevations above 800 IU/day.

Drugs and Supplements That Lower PIVKA-II

While most drug interferences push PIVKA-II upward, several agents can suppress it, potentially masking HCC or creating a false sense of adequate vitamin K status.

Vitamin K Supplementation

This is the most obvious confounder in the other direction. Phytonadione (K1) at 10 mg orally can normalize PIVKA-II within 24 to 48 hours, even in patients with subclinical deficiency. Menaquinone-7 (MK-7) supplements, popular in the bone health market, produce a slower but sustained reduction in PIVKA-II over 4 to 6 weeks at typical doses of 100 to 200 mcg daily 13.

For HCC surveillance purposes, this normalization is a problem. Dr. Jorge Marrero, who led several landmark PIVKA-II validation studies at the University of Michigan, has stated: "Patients undergoing PIVKA-II surveillance for hepatocellular carcinoma should disclose all vitamin K-containing supplements, as even over-the-counter MK-7 products can suppress tumor-related elevations" 3.

High Vitamin K Dietary Intake

While not a drug, consistently high dietary intake of green leafy vegetables (kale, spinach, collard greens) provides 300 to 900 mcg of phylloquinone daily, far exceeding the adequate intake of 90 to 120 mcg. This can keep PIVKA-II suppressed even in early HCC.

How to Interpret PIVKA-II When Patients Are on Interfering Drugs

A systematic approach is necessary. Before ordering PIVKA-II, review the medication list for every agent discussed above.

Step-by-Step Medication Review

First, check for vitamin K antagonists. If the patient takes warfarin, acenocoumarol, or phenprocoumon, PIVKA-II is unreliable. Use AFP and imaging alone for HCC surveillance, or arrange a supervised warfarin hold with bridging anticoagulation.

Second, check for broad-spectrum antibiotics, especially NMTT cephalosporins. If the patient completed a course within the past 14 days, either delay the draw or supplement with vitamin K1 and recheck.

Third, check for orlistat, cholestyramine, or other fat-blocking agents. Supplement with oral vitamin K1 for at least 7 days before the scheduled draw.

Fourth, ask about supplements. High-dose vitamin E (above 400 IU) may falsely raise PIVKA-II. MK-7 supplements may falsely lower it. Document both.

Assay-Specific Considerations

Two major commercial assays measure PIVKA-II: the LUMIPULSE system (Fujirebio) and the ARCHITECT platform (Abbott). Cutoff values and units differ. The LUMIPULSE reports in mAU/mL with a typical HCC cutoff of 40 mAU/mL. The ARCHITECT reports in ng/mL with varying institutional cutoffs. Always interpret against the reference range supplied by the performing laboratory 14.

Normal Range and What Abnormal Results Mean

The reference range for PIVKA-II in most laboratories is <40 mAU/mL (LUMIPULSE) or <7.5 ng/mL (some ELISA-based assays).

High PIVKA-II

A PIVKA-II above the reference range, after excluding drug interference, suggests one of three clinical scenarios. Hepatocellular carcinoma is the most concerning, particularly when AFP is also elevated. Vitamin K deficiency from malnutrition, malabsorption (celiac disease, short bowel syndrome, cystic fibrosis), or prolonged fasting is the second possibility. Obstructive jaundice, where bile flow is blocked and fat-soluble vitamin absorption is impaired, is the third.

Low PIVKA-II

A PIVKA-II within or below the normal range generally indicates adequate vitamin K status and no HCC signal. If the result is unexpectedly low in a patient with known HCC risk factors (cirrhosis, chronic hepatitis B), consider whether vitamin K supplementation or high dietary intake is suppressing the marker.

Putting It Together: When to Trust (and When Not to Trust) This Test

PIVKA-II is a powerful biomarker. Combined with AFP, it detects early-stage HCC with a sensitivity of approximately 80%, compared with 63% for AFP alone and 71% for PIVKA-II alone 2. But its clinical value depends entirely on knowing what medications the patient takes.

No PIVKA-II result should be acted upon without a concurrent medication reconciliation. For patients on warfarin, the test is uninformative. For patients on broad-spectrum antibiotics, orlistat, or anticonvulsants, the test requires context and may require a washout period. For patients taking vitamin K supplements, the test may be falsely reassuring.

The most reliable PIVKA-II draw occurs in a patient who has been off all interfering medications for at least 2 weeks, is not taking vitamin K supplements, and is eating a normal (not unusually high or low in green vegetables) diet. When those conditions are met, PIVKA-II at <40 mAU/mL provides strong negative predictive value for HCC in at-risk populations.